We combine decades of expertise with advanced technologies to lead in the development and manufacturing of the highest quality controlled substance APIs and drug product.
Benuvia stands at the forefront of small molecule controlled substance development, manufacturing, and commercialization. Our expertise spans cannabinoids, psychedelics, and Schedule I–V compounds. Rigorous Quality Control processes ensure every product meets the highest standards of purity, potency, and compliance, safeguarding integrity at every stage. Combined with our deep understanding of DEA, FDA, and global regulatory standards, we provide unparalleled reliability and success in even the most complex markets.
Benuvia combines advanced expertise and cutting-edge facilities to manufacture controlled substance small molecule APIs and drug products with precision and compliance. Our cGMP-certified processes ensure unmatched quality, making us the trusted choice for synthetic cannabinoids and psychedelics.
IUPAC Chemical Name:
2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
Common Synonyms:
(-)-trans-Cannabidiol, Delta-1(2)-trans-Cannabidiol, Resorcinol 2-p-mentha-1,8-dien-3-yl-5-pentyl-trans-(-)-
CAS Number: 13956-29-1
DEA Schedule: Not Scheduled
Controlled Substances Code Number (CSCN): NA
Cannabidiol (CBD) is a non-psychoactive phytocannabinoid derived from the Cannabis sativa plant. It is widely studied for its potential therapeutic applications, particularly in the treatment of epilepsy, anxiety, chronic pain, and inflammation. CBD interacts with the endocannabinoid system, influencing receptors such as CB1 and CB2, as well as other receptors including TRPV1 and 5-HT1A, contributing to its diverse pharmacological effects. Notably, CBD has been approved by the FDA for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in the form of Epidiolex. Additionally, CBD demonstrates anti-inflammatory, anxiolytic, and neuroprotective properties.
CBD is synthetically produced and available as GLP material suitable for preclinical toxicology studies or as non-GMP research grade material. It is manufactured in compliance with Good Manufacturing Practices (GMP), making it suitable for FDA-regulated human clinical trials.
As Controlled Substance Experts, we bring unmatched knowledge and precision to every stage of API development and manufacturing. Explore our detailed white paper to discover how Benuvia’s innovative solutions, cutting-edge technologies, and regulatory expertise can help you navigate challenges, ensure compliance, and achieve success in our highly specialized field.
Mr. Awuah-Mensah has a Pharm.D. degree with over 13 years of experience in the Pharmaceutical Industry. Prior to joining Benuvia, Mr. Awuah-Mensah worked for Insys Manufacturing, Austin Pharma, and Hospira. Godfrey is responsible for API and Drug Product Manufacturing.
"*" indicates required fields
Notifications
